Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and IDEAYA Biosciences (IDYA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY) and IDEAYA Biosciences (IDYA).
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Incyte (INCY)
UBS analyst Ashwani Verma maintained a Hold rating on Incyte yesterday and set a price target of $103.00. The company’s shares closed last Monday at $100.64.
According to TipRanks.com, Verma is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.53 average price target, which is a 7.5% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
IDEAYA Biosciences (IDYA)
UBS analyst Michael Yee reiterated a Buy rating on IDEAYA Biosciences yesterday and set a price target of $50.00. The company’s shares closed last Monday at $31.48.
According to TipRanks.com, Yee is a 1-star analyst with an average return of
IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $54.00, which is an 87.2% upside from current levels. In a report issued on June 2, TipRanks – Google also upgraded the stock to Buy with a $32.00 price target.
Read More on INCY:
